Adverse events that were observed in this study are consistent with what has been reported with single-agent ramucirumab in other trials.17 Notably, the incidence of hypertension in patients with NETs who receive a VEGF-targeted therapy is higher than in patients with other tumors. This evidence concerns the gene VEGFA and hypertensive disorder.